NATIONAL CANCER CENTER Patent applications |
Patent application number | Title | Published |
20160130663 | METHOD FOR PREDICTING RESPONSE TO CANCER TREATMENT - It has been found that BRG1 and BRM have a synthetic-lethal relationship, and that a treatment for inhibiting BRM is a promising approach for treating a BRG1-deficient cancer having no mutation in known therapeutic target genes. Moreover, it has also been revealed that, in this therapeutic strategy, a BRM inhibitor may be administered to a cancer patient after the selection based on BRG1 function suppression, thus enabling an efficient treatment based on the companion diagnosis. | 05-12-2016 |
20150265731 | METHOD TO IMPROVE THE TUMOR DIAGNOSTIC EFFICIENCY OF MULTIVALENT LIGANDS BY REGULATING THE STOICHIOMETRIC RATIO BETWEEN INNER SURFACE FUNCTIONALITIES AND LIGAND MOIETIES FOR TUMOR TARGETING - Disclosed herein is a method of improving tumor diagnostic efficiency of multivalent ligands by regulating the stoichiometric ratio between inner surface functionalities and ligand moieties for tumor targeting, and the multivalent ligands for tumor diagnosis. | 09-24-2015 |
20150240313 | USE OF ADCY3 FOR DIAGNOSIS AND TREATMENT OF GASTRIC CANCER - The present invention relates to: a composition for detecting a gastric cancer marker comprising a preparation for measuring the expression level or methylation level of mRNA of ADCY3 or a protein thereof; a kit for diagnosing gastric cancer, containing the composition; a method for diagnosing gastric cancer by treating a biological sample with the preparation to ascertain whether a material for complementarily binding to the preparation exists and comparing the amount thereof with a control group; a composition for treating and preventing gastric cancer, containing a preparation capable of inhibiting ADCY3 polynucleotide or ADCY3 polypeptide; and a method for treating gastric cancer by administering the composition to an individual. According to the present invention, it is possible to diagnose gastric cancer with high diagnostic sensitivity and specificity using ADCY3 as a marker for diagnosing gastric cancer, and thus can greatly contribute to reducing mortality due to gastric cancer. | 08-27-2015 |
20150218514 | PROMOTER OF DIFFERENTIATION FROM HEPATIC PROGENITOR CELL INTO HEPATIC CELL, AND USE THEREOF - The present invention provides a promoter of differentiation from a hepatic progenitor cell into a hepatocyte, which contains a substance that suppresses expression of Dnmt-1 or a substance that inhibits the function of Dnmt-1 as an active ingredient, and a method of producing a hepatocyte (preferably hepatocyte with high maturity) from a hepatic progenitor cell. | 08-06-2015 |
20150198598 | KIT FOR DIAGNOSING MALIGNANT MELANOMA - Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies. | 07-16-2015 |
20150197747 | AGENT FOR TREATING CANCER - [Problem] To provide the following: an agent for treating cancer, particularly an agent for inhibiting cancer cell proliferation or an agent for inhibiting or preventing cancer metastasis; drug that uses the agent; a method for assessing the effect of cancer treatment; a method for estimating the prognosis of cancer treatment; a method for screening for a substance having a cancer proliferation-inhibiting effect; and a method for screening a substance having a cancer metastasis-impeding effect. | 07-16-2015 |
20150191791 | FGFR2 FUSION GENE - In order to identify genes that can serve as indicators for predicting the effectiveness of drug treatments in cancers and provide novel methods for predicting the effectiveness of treatments with drugs targeting said genes, transcriptome sequencing was performed of biliary tract cancer. As a result, in-frame fusion transcripts between the FGFR2 gene and other gene (BICC1 or AHCYL1 gene) were identified. It was also found that said gene fusions induce activation of FGFR2 protein, thereby causing canceration of cells. Further, it was demonstrated that the FGFR2 protein activation and canceration caused by said gene fusions can be suppressed by using an FGFR2 inhibitor, and that treatments with an FGFR2 inhibitor are effective in patients with detection of said gene fusions. | 07-09-2015 |
20150184248 | METHOD FOR DETECTING PANCREATIC CANCER AND DETECTION KIT - An object of the invention is to provide a simple and easy method for detecting pancreatic cancer having high sensitivity and specificity or risk of the pancreatic cancer. | 07-02-2015 |
20150147747 | COMPOSITION COMPRISING OF A CONDUCTING POLYMER FOR DETECTING, CAPTURING, RELEASING, AND COLLECTING CELL - The present invention relates to a composition in which a conducting polymer is doped with a dopant, and a diagnostic apparatus, and more particularly, to a composition which is used to diagnose a disease and detect a biomaterial and also used for qualification and diagnosis by effectively and non-destructively collecting a captured biomaterial. Further, the composition can maximize capturing efficiency by being attached to a surface of a nano-structured scaffold and can be used as an ultrahigh-sensitive sensor using various linked bodies. | 05-28-2015 |
20150133656 | NOVEL BICYCLIC THIAZOLE COMPOUNDS - The present invention relates to novel bicyclic thiazole compounds that inhibit Traf2- and Nck-interacting kinase (TNIK), and as such are useful as TNIK inhibitors administered to cancer patients, especially to solid cancer patients such as colorectal cancer, pancreatic cancer, non-small cell lung cancer, prostate cancer or breast cancer. The bicyclic thiazole compounds are showed by a next formula (I). (wherein R | 05-14-2015 |
20150118681 | METHOD FOR PREDICTING PROGNOSIS OF RENAL CELL CARCINOMA - In order to provide a method for detecting an unfavorable prognostic risk of renal cell carcinoma easily with quite high sensitivity and specificity, a methylome analysis was performed on normal renal tissues, and non-cancerous tissues and renal cell carcinomas derived from patients with renal cell carcinomas. The result revealed that it was possible to detect an unfavorable prognostic risk of renal cell carcinoma by detecting a DNA methylation level at at least one CpG site of FAM150A, GRM6, ZNF540, ZFP42, ZNF154, RIMS4, PCDHAC1, KHDRBS2, ASCL2, KCNQ1, PRAC, WNT3A, TRH, FAM78A, ZNF671, SLC13A5, and NKX6-2 genes. | 04-30-2015 |
20150025618 | PROJECTION-TYPE PARTIALLY DUAL-STRUCTURED STENT - Disclosed is a partly projected double-walled stent. Provided is a technique for allowing a stent to be easily secured in a conduit in a human body by a protrusion coupled to a body. According to the stent, first and second ridges of the protrusion are crossed and projected to be inclined in opposite directions, and thus the partly projected double-walled stent is rigidly secured in the conduit in the human body without being displaced in the left and right directions by an external force. Also, the number of protrusions can be adjusted according to circumstances so as to simplify a manufacturing process and reduce manufacturing costs. Further, a cover coupled to the body prevents a lesion portion from penetrating into the partly projected double-walled stent, thus preventing re-stenosis caused by the lesion portion. | 01-22-2015 |
20140286905 | RECOMBINANT ADENOVIRUS COMPRISING TRANS-SPLICING RIBOZYME AND CANCER-TREATING GENE, AND USE THEREOF - The present invention relates to: a recombinant adenovirus comprising a polynucleotide, which encodes a trans-splicing ribozyme-HSVtk composite relating to a cancer-specific gene, and a cancer-treating gene; a pharmaceutical composition for preventing or treating cancer, containing the recombinant adenovirus as an active ingredient; and a method for treating cancer, comprising the step of administering the recombinant adenovirus or the pharmaceutical composition to an individual requiring treatment. The recombinant adenovirus of the present invention shows selectivity for a cancer cell by a trans-splicing ribozyme relating to a cancer-specific gene and an increased anticancer activity by a cancer-treating gene, and thus can be widely used for the effective prevention and treatment of cancer. | 09-25-2014 |
20140248261 | ANTIBODY AGAINST MUTANT ALPHA-ACTININ-4 - An antibody against mutant α-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of α-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region. | 09-04-2014 |
20140243392 | MicroRNA-Based Methods and Assays for Osteosarcoma - Provided are methods and compositions useful in the diagnosis, treatment, and monitoring of osteosarcoma. Antisense to certain microRNA (miRNA) found to be associated with cancer stem cells (CSCs) or tumor-initiating cells (TICs) of osteosarcoma are useful to suppress tumor growth and metastasis, and prolong survival. Antisense oligonucleotides to miR-133a are synergistic in combination with standard chemotherapy such as cisplatin in the treatment of osteosarcoma. | 08-28-2014 |
20140242049 | MUTANT CTLA4 GENE TRANSFECTED T CELL AND COMPOSITION INCLUDING SAME FOR ANTICANCER IMMUNOTHERAPY - A transformed T-cell for T-cell therapy, and a composition including the same for anticancer immunotherapy. More particularly, the transformed T-cell is characterized by the transfection of a gene for coding a chimera protein. The T-cell, to which the gene for coding the chimera protein is transected, may improve the therapeutic effects induced by immune tolerance of cancer cells, and furthermore maximize anti-cancer effects by activating signal transduction to induce the activation of T-cells. Also, the disclosure allows treatments that minimize side effects such as the development of autoimmune diseases due to systematic T-cell activation. | 08-28-2014 |
20140221404 | FUSION GENE OF Kif5b GENE AND Ret GENE, AND METHOD FOR DETERMINING EFFECTIVENESS OF CANCER TREATMENT TARGETING FUSION GENE - In order to identify a gene that can serve as an indicator for predicting the effectiveness of a drug treatment of cancer and to provide a novel method for predicting the effectiveness of a drug treatment targeting said gene, lung adenocarcinomas were subjected to whole-transcriptome sequencing. As a result, in-frame fusion transcripts between the KIF5B gene and the RET gene were identified. The KIF5B-RET gene fusions were detected in 6 out of 319 (2%) LADC specimens from Japanese individuals and 1 out of 80 (1%) LADC specimens from U.S.A. individuals. None of the seven subjects revealed known activating mutations such as EGFR, KRAS or ALK oncogenes; thus, said gene fusions were found to be responsible mutations (driver mutations) for oncogenesis. Since said gene fusions are considered to induce constitutive activation of RET tyrosine kinase protein, it was found that treatments with RET tyrosine kinase inhibitors are effective in patients with detection of said gene fusions. | 08-07-2014 |
20140186261 | ANTI-TUMOR AGENT AND ANTI-TUMOR KIT - An anti-tumor agent comprising combination of a radioactive diacetyl-bis(N4-methylthiosemicarbazone) copper complex and a metabolic inhibitor. | 07-03-2014 |
20140186260 | RADIOPHARMACEUTICAL AND PHARMACEUTICAL KIT - A radiopharmaceutical comprising combination of a particular radioactive dithiosemicarbazone copper complex, and a chelating agent comprising a multidentate ligand having a maximum dentate number of 2 or more to 4 or less. | 07-03-2014 |
20140137274 | INDUCED MALIGNANT STEM CELLS | 05-15-2014 |
20140109247 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 04-17-2014 |
20140072566 | NOVEL EPITOPE FOR SWITCHING TO TH2 CELL AND USE THEREOF - The present invention relates to a novel epitope to convert T cell to type 2 helper T (T | 03-13-2014 |
20140072565 | NOVEL EPITOPE FOR SWITCHING TO TH17 CELL AND USE THEREOF - The present invention relates to a novel epitope to convert T cell to type 17 helper T (T | 03-13-2014 |
20140065152 | NOVEL EPITOPE FOR SWITCHING TO TH1 CELL AND USE THEREOF - The present invention relates to a novel epitope that converts T cell to type 1 helper T (T | 03-06-2014 |
20140037770 | Burdock Fruit Extract Containing Arctigenin and Method for Producing Same - The present invention is intended to provide a burdock fruit extract comprising arctigenin and arctiin at a definite ratio and a method for producing the same. More particularly, the present invention is intended to provide a method for producing a burdock fruit extract comprising arctigenin and arctiin at a weight ratio of approximately 1:1. | 02-06-2014 |
20140017686 | METHOD FOR ASSESSING RISK OF HEPATOCELLULAR CARCINOMA - The present invention aims at providing a method for assessing risk of hepatocellular carcinoma with high sensitivity and specificity. Extracted were 30 regions containing 45 CpG sites which have DNA methylation levels significantly different between in normal liver tissue samples and in noncancerous liver tissue samples from patients with hepatocellular carcinoma. It was found that the noncancerous liver tissue samples from patients with HCC were able to be assessed for risk of hepatocellular carcinoma by setting cutoff values for distinguishing between the normal liver tissue samples and the noncancerous liver tissue samples from patients with HCC for the extracted 30 regions. | 01-16-2014 |
20140005075 | Composition for aggregating biological sample | 01-02-2014 |
20130345763 | PIN ASSEMBLY FOR OPERATION CAPABLE OF INTRODUCING DRUG - A pin assembly for operation includes a hollow pin for operation having a plurality of side holes defined through an outer surface thereof and a head which is closed or open due to the presence of a through-hole; a hollow support having a pin fastening part formed therein in the shape of a groove to fasten one end of the pin for operation, and being open at both ends thereof, and a hollow injector for insertion into an insertion hole formed in the support, wherein the hollow pin for operation is fastened to the pin fastening part of the support, and by applying external force to one end of the support, the hollow pin for operation is inserted into a bone. | 12-26-2013 |
20130325103 | ABDOMINAL CAVITY-VEIN SHUNT STENT - An abdominal cavity-vein shunt stent provided for transporting ascites accumulated in the abdominal cavity of a patient to a vascular system, includes: a stent body which extends cylindrically long and which has one end disposed in the intrahepatic vein, and the other end piercing the liver parenchyma and disposed in the abdominal cavity; and a one-way valve which is disposed in the stent body, which is opened to drain ascites into the intrahepatic vein when a differential pressure obtained by subtracting the pressure of the intrahepatic vein from the pressure in the abdominal cavity is not lower than a predetermined value, and which is closed when the differential pressure is lower than the predetermined value. | 12-05-2013 |
20130309169 | Sentinel Lymph Node Marker Capable of Multi-Mode Imaging - The present invention relates to a sentinel lymph node marker comprising an albumin; a radioactive isotope and/or near infrared dye which is bound to the albumin; and a visible dye which is bound to the albumin, a preparation method thereof, a kit for multimode imaging of a sentinel lymph node to prepare the sentinel lymph node marker, and a method for multimode imaging of a sentinel lymph node using the same. The sentinel lymph node marker of the invention remains in the sentinel lymph node for a long period of time and allows for multimode imaging of the sentinel lymph node. Thus, using this marker the sentinel lymph node can be accurately identified in vivo by near infrared imaging and/or gamma imaging without incision of skin, and the location of the identified sentinel lymph node can be precisely identified with the naked eye during a surgical operation of removing the identified sentinel lymph node. | 11-21-2013 |
20130231869 | APPARATUS FOR CANCER DIAGNOSIS - The present invention provides an apparatus for screening cancer, which reads low-mass ion mass spectrum for diagnosing cancer based on biostatistical analysis with respect to low-mass ions extracted from biological materials, and diagnoses cancer using the low-mass ion spectrum. An apparatus for cancer diagnosis, including a low-mass ion detecting unit which detects mass spectra of low-mass ions of biological materials; a cancer diagnosing unit which compares and analyzes patterns of mass spectra and diagnoses cancer; a display unit which displays cancer diagnosis information from the cancer diagnosing unit. | 09-05-2013 |
20130230869 | ANTIBODY AGAINST COLORECTAL CANCER MARKER - The purpose of the present invention is to provide a novel monoclonal antibody which binds to SLC6A6 or an extracellular domain thereof. The present invention relates to a monoclonal antibody which recognizes native SLC6A6 or a polypeptide of an extracellular domain of SLC6A6. | 09-05-2013 |
20130206977 | METHOD FOR CRYSTALLIZING LOW MASS IONS FOR DIAGNOSING COLORECTAL CANCER AND METHOD FOR DIAGNOSING COLORECTAL CANCER USING SAME - The present invention provides a method for crystallizing low mass ions for diagnosing colorectal cancer by using a MALDI-TOF mass spectrometer to biostatistically analyze low mass ions, which are extracted from a biological sample, and a method for providing information for diagnosing colorectal cancer using same. The present inventions can provide a diagnostic method, which requires low cost and a short time for analysis, can analyze large areas, and which can provide superior and credible discriminations. | 08-15-2013 |
20130198876 | INDUCED MALIGNANT STEM CELLS OR PRE-INDUCTION CANCER STEM CELLS CAPABLE OF SELFREPLICATION OUTSIDE OF AN ORGANISM, PRODUCTION METHOD FOR SAME, AND PRACTICAL APPLICATION FOR SAME - The present invention provides an induced cancer cell capable of self-replication in vitro which is useful in cancer therapy research and the research for cancer-related drug discovery, processes for production thereof, cancer cells induced by the malignant cells, and applications of these cells. | 08-01-2013 |
20130149302 | THERAPEUTIC AGENTS FOR PANCREATIC CANCER - We achieved the present invention on the basis of the finding that an excellent therapeutic effect against pancreatic cancer can be obtained by administering an XL-6 inhibitor and an antimetabolite to pancreatic cancer patients. We also found that metastatic lesions from human pancreatic cancer can be reduced and ascites can be eliminated. | 06-13-2013 |
20130137592 | BIOMARKERS - An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1β, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor. | 05-30-2013 |
20130087721 | CHARGED PARTICLE DOSE SIMULATION DEVICE, CHARGED PARTICLE BEAM IRRADIATION DEVICE, CHARGED PARTICLE DOSE SIMULATION METHOD, AND CHARGED PARTICLE BEAM IRRADIATION METHOD - A simulation device includes an input unit which receives an input of simulation data including material information of the irradiation target and irradiation information of a charged particle beam, and an arithmetic unit which calculates the dose distribution of the charged particle beam in the irradiation target on the basis of simulation data received by the input unit and the dose distribution kernel. The arithmetic unit segments the charged particle beam spread to a predetermined range at an intermediate portion in the traveling direction of the charged particle beam, hypothesizes a plurality of virtual shapes having conical spread with a segmented position as a start point, and calculates the dose distribution of the charged particle beam in the irradiation target on the basis of simulation data received by the input unit and a plurality of virtual shapes of the charged particle beam. | 04-11-2013 |
20130085081 | RISK PREDICTION OF DEVELOPING DRUG-INDUCED LUNG INJURY AND DETECTION METHOD AND KIT OF GENE FOR RISK PREDICTION - Disclosed are a method of detecting the presence or absence of a single nucleotide polymorphism of a gene, for prediction of the risk of developing drug-induced lung injury, or for improving a therapeutic method, and a kit for carrying out the detection method. The detection method is characterized by comparing an ABCB1 gene in a biological sample with a wild-type ABCB1 gene to detect the presence or absence of a single nucleotide polymorphism in the ABCB1 gene in the biological sample, in particular, by determining the nucleotide at position 3751 of the CDS of the ABCB1 gene. The kit comprises an oligonucleotide probe which specifically binds to a single nucleotide polymorphism in an ABCB1 gene under selective binding conditions, or an oligonucleotide primer which amplifies a nucleic acid sequence comprising a single nucleotide polymorphism in an ABCB1 gene. | 04-04-2013 |
20130071931 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY - A method for hepatic differentiation of a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is presented. More specifically, a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is cultured for 1 to 4 weeks in the presence of a TGF-β inhibitor, whereby the hepatic differentiation of the stem cell is realized. | 03-21-2013 |
20130045500 | CELL EVALUATION METHOD - The present invention provides a method of figuring out an effect of a medicine exerting on the same cell quantitatively over a time. A cell evaluation method includes a step of culturing cells on a cell-culture base material that is capable of culturing spheroids, and a step of measuring a change over a time in the number of the spheroids formed through the former step or a percentage of the spheroids formed through the former step relative to an entire cultured cell. | 02-21-2013 |
20130045486 | Composition for Cancer Prognosis Prediction Comprising Anti-TMAP/CKAP2 Antibodies - The present invention relates to an antibody which specifically binds to TMAP (tumor associated microtubule associated protein)/CKAP2 (cytoskeleton associated protein 2) or a fragment thereof, and a method for identifying the presence or absence of mitosis and a method for diagnosing cancer prognosis using the same. More specifically, the present invention relates to a composition for diagnosing cancer prognosis comprising an anti-TMAP/CKAP2 antibody or an antigen-binding site thereof, a method for detecting TMAP/CKAP2 using the composition, an anti-TMAP/CKAP2 antibody for diagnosing cancer prognosis, a method for providing information for diagnosing cancer prognosis using the composition, a method for screening a cancer therapeutic agent comprising the step of determining changes in the level of TMAP/CKAP2 antigen-antibody reaction by the treatment of a candidate substance, and a composition for determining cell-division cycles using the composition. | 02-21-2013 |
20130023045 | INDUCED HEPATIC STEM CELL AND PROCESS FOR PRODUCTION THEREOF, AND APPLICATIONS OF THE CELL - The present invention relates to an induced hepatic stem cell defined as follows, a process for production thereof, and applications of the cell, which are useful in safety tests, toxicity tests, metabolism tests, drug interaction tests, antiviral activity tests, screening tests for pharmaceuticals such as hyperlipidemic therapeutics, hypertension therapeutics, low-molecular weight compound medicaments, and antibody medicaments, screening for targets in drug discovery, preparation of animal models, production of hepatocyte-produced proteins, and in regenerative medicine. The induced hepatic stem cell of the present invention is characterized by at least satisfying the following requirements (1)-(3): (1) it expresses at least 15 genes as selected from the group of the genes which are marker genes for an embryonic stem cell; (2) it has properties of a hepatocyte; and (3) it can be subjected to expansion culture or passage culture for at least 3 days. | 01-24-2013 |
20120272349 | METHOD FOR CONSTRUCTING CHIMERIC RAT USING RAT EMBRYONIC STEM CELLS - The present invention provides a preparation method of a chimeric embryo and a chimeric rat, which is characterized by contacting a rat pluripotent stem cell and a host embryo in the presence of an ES cell differentiation inhibitor. The method includes (a) a step for contacting a fertilized host embryo collected from a female rat and a rat pluripotent stem cell in the presence of an ES cell differentiation suppressant, and (b) a step for culturing the host embryo in contact with the rat pluripotent stem cell to form a chimeric embryo. | 10-25-2012 |
20120252881 | THERAPEUTIC AGENT FOR TUMOR - The present invention provides a therapeutic agent for a tumor, particularly a therapeutic agent for drug-resistant cancer, an agent for suppression or prophylaxis of tumor metastasis, and an agent for suppression or prophylaxis of cancer recurrence, containing a nucleic acid containing miR27b or a nucleotide having a nucleotide sequence having an identity of 70% or more with the nucleotide sequence shown by SEQ ID NO: 1 and having a function equivalent to miR27b. | 10-04-2012 |
20120201837 | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER - Disclosed are a cancer marker-detecting composition comprising an agent for measuring an mRNA or protein expression level of eIF3m, a cancer diagnosis kit comprising the same, a method for detecting an eIF3m polynucleotide or protein by treating a biological specimen with the agent to detect a substance binding specifically to the agent and quantitatively comparing the substance between a subject and a normal control, and a method for the treatment and prevention of cancer comprising an agent for down-regulating the expression of an eIF3m polynucleotide or protein. | 08-09-2012 |
20120178633 | DIAGNOSTIC COMPOSITION FOR AUTOIMMUNE DISEASES COMPRISING AGENT MEASURING CD3Z GENE METHYLATION LEVEL AND A METHOD FOR DIAGNOSING AUTOIMMUNE DISEASES USING THE SAME - The present invention relates to a diagnostic composition for autoimmune diseases, comprising agent measuring a methylation level of CD3Z gene, a diagnostic method and a kit using the same. More particularly, the present invention relates to a composition for diagnosing autoimmune diseases according to the methylation level of CD3Z gene, or additionally ADA or VHL gene, and a method for diagnosing autoimmune diseases by measuring the methylation level. The methylation of any one or more of the ADA, VHL, and CD3Z genes of the present invention is specific to autoimmune diseases, and thus the composition comprising an agent measuring a methylation level of the present invention can be used for the diagnosis of autoimmune diseases. | 07-12-2012 |
20120142092 | RAT EMBRYONIC STEM CELL - The present invention provides a rat embryonic stem cell characterized by having the following properties of (a) expressing Oct3/4 gene and Nanog gene, (b) positive for alkaline phosphatase activity, (c) having an embryoid body forming ability, (d) expressing SSEA (Stage-Specific Embryonic Antigen)-1 and SSEA-4, (e) having the same number of chromosomes as does a normal rat cell, (f) capable of being subcultured and holding the undifferentiated state, (g) having in vitro pluripotency, (h) having a potential to differentiate for cells of three embryonic germ lineages, (i) having teratoma formation ability, and (j) having an ability to produce a chimeric rat, a method of establishing the aforementioned rat embryonic stem cell and the like. | 06-07-2012 |
20120068631 | CHARGED PARTICLE BEAM RADIATION CONTROL DEVICE AND CHARGED PARTICLE BEAM RADIATION METHOD - Provided is a charged particle beam radiation control device that controls radiation of a charged particle beam, the charged particle beam radiation control device including: a controller which controls an acceleration voltage for accelerating charged particles, wherein the controller includes a set acceleration voltage controller which selects a non-radiation state of a charged particle beam by setting an acceleration voltage of a radiation state of the charged particle beam to a reference acceleration voltage and changing the acceleration voltage to a set acceleration voltage larger or smaller than the reference acceleration voltage. | 03-22-2012 |
20110287036 | NOVEL CANCER TARGETING THERAPY USING COMPLEX OF SUBTANCE CAPABLE OF BINDING SPECIFICALLY TO CONSTITUENT FACTOR OF CANCER STROMA AND ANTI-TUMOR COMPOUND - The present invention is intended to provide a pharmaceutical for tumor treatment that stays specifically in interstitium for a long time and exhibits an effect, and provides a complex consisting of a substance having specific binding affinity for stroma and an antitumor compound bound to the substance via a linker. | 11-24-2011 |
20110262425 | THERAPEUTIC AGENT FOR MLL LEUKEMIA AND MOZ LEUKEMIA OF WHICH MOLECULAR TARGET IS M-CSF RECEPTOR, AND USE THEREOF - An objective of the present invention is to provide therapeutic agents for MLL leukemia and MOZ leukemia, which include an M-CSF receptor inhibitor as an active ingredient. Another objective of the present invention is to provide methods of screening for pharmaceutical compositions that treat or prevent leukemia by suppressing the expression or activity of M-CSF receptor. Still another objective of the present invention is to provide methods of testing for leukemia, which include the step of determining the expression level of an M-CSF receptor. The present inventors conducted dedicated studies, and as a result revealed that the M-CSF receptor (M-CSFR, CSF1R, c-FMS, or CD115) is highly expressed in cells having the activity of inducing MLL or MOZ leukemia (leukemia stem cells), both of which are intractable acute leukemia. Specifically, the present inventors discovered that the M-CSF receptor signal is closely associated with the leukemia onset. | 10-27-2011 |
20110250584 | Method for Screening Cancer Therapeutic Agent Using Galectin-3, GSK-3Betta, and Fascin-1 - Disclosed is a method for screening a novel cancer therapeutic agent. The cancer therapeutic agent exhibits down-regulation of galectin-3 and fascin-1 or interferes with the interaction between galectin-3 and GSK-3β. | 10-13-2011 |
20110152121 | APPARATUS AND METHOD FOR MULTIPLE IMMUNOASSAYS ON A CHIP - Provided are a multiple immunoassay apparatus on a chip in which a structure comprising multiple microfluidic channels is associated with a tissue sample, which allows immunohistochemical reactions to be conducted therein, to examine various markers specific for certain diseases, and a method for performing multiple immunoassays using the same. The multiple immunoassay apparatus comprises: at least one antibody-introducing unit through which at least one antibody is introduced into the apparatus; at least one reaction unit in which the antibody reacts with a sample in an immunohistochemical pattern; and at least one fluid outlet through which a fluid including the antibody is discharged outside the apparatus. | 06-23-2011 |
20110150869 | Neuroinvasion Inhibitor - The present inventors discovered that neural invasion is suppressed by inhibiting IL-6 in a model for neural invasion of pancreatic cancer, and completed the present invention. The present inventors also demonstrated that: an IL-6 receptor is expressed in cells of human pancreatic cancer cell lines; and IL-6 enhances the chemotactic and migratory activities and intracellular signaling of pancreatic cancer cells; and thus pancreatic cancer can be treated by inhibiting IL-6. Furthermore, the present inventors found that neural invasion of human pancreatic cancer can be suppressed, from the results of administering IL-6 inhibitors to neural invasion model mice. | 06-23-2011 |
20110136246 | NOVEL ONCOGENE NRF2 - The present invention provides a marker which can be used as an indicator for efficacy prediction of an mTOR related anticancer agent or prognostic prediction, and a novel anticancer agent. The present invention provides a method for efficacy evaluation of a cancer drug, and, specifically, a prediction method for the efficacy of an mTOR-related cancer drug by detecting NRF2 abnormality. In addition, the present invention provides a prognostic prediction method for cancer, and, specifically, a prediction method for the prognosis of cancer by detecting NRF2 abnormality. Furthermore, the present invention provides a novel anticancer agent that targets NRF2. | 06-09-2011 |
20110124712 | ANTI-CANCER COMPOSITION COMPRISING MICRORNA MOLECULES - Disclosed is an anticancer composition for the treatment of hypoxia-induced angiogenesis-associated diseases including cancers. It comprises a microRNA-125 nucleic acid molecule. Also, methods of inhibiting angiogenesis, suppressing the invasion and metastasis of cancer cells, and treating cancers are provided. | 05-26-2011 |
20110105352 | METHOD FOR MEASURING CHROMOSOME, GENE OR SPECIFIC NUCLEOTIDE SEQUENCE COPY NUMBERS USING SNP ARRAY - The present invention relates to a method for measuring the copy number of a chromosome, gene or specific nucleotide sequence, comprising the steps of: (a) mixing a homozygous DNA with a test sample DNA; (b) analyzing the DNA mixture by means of SNP array; and (c) determining the copy number of a chromosome, gene, or specific nucleotide sequence by measuring the difference in signal output from the homozygous DNA and the test sample DNA. | 05-05-2011 |
20110091471 | TREATMENT METHOD FOR EPITHELIAL CANCEROUS ORGANISM - It is an object of the present invention to provide a novel method for decreasing the number of clinical cases for which trastuzumab administration is ineffective. The present invention provides a method for treating a living individual with epithelial cancer comprising:
| 04-21-2011 |
20110028535 | OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS - Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided. | 02-03-2011 |
20110021601 | COMPOSITION CONTAINING MICRORNA-21 INHIBITOR FOR ENHANCING RADIATION SENSITIVITY - Disclosed is a radiation sensitivity-enhancing composition in which a microRNA-21 inhibitor acts as an active ingredient. The microRNA-21 inhibitor is an antisense nucleic acid molecule binding complementarily to microRNA-21. The composition can be administered to a patient in conjunction with irradiation. The inhibitor can act as a radiosensitizer, enhancing the therapeutic effect of such irradiation on cancer high in microRNA-21 expression level, particularly, glioma. | 01-27-2011 |
20100316635 | KIT FOR DIAGNOSIS OF BREAST CANCER USING HERCEPTIN, A COMPOSITION COMPRISING HERCEPTIN AND A METHOD FOR DETECTING HERCEPTIN-SENSITIVE HER2 OVEREXPRESSED CELL USING THE SAME - A kit and a composition comprising Herceptin, an antibody binding specifically to HER2, based on detecting Herceptin-sensitive HER2-overexpressing cells are provided for diagnosing cancer. A method of detecting Herceptin-sensitive HER2-overexpressing cells using the same is also provided. | 12-16-2010 |
20100286675 | Surgical instrument - Provided is surgical instrument which can provide a field of view over surgical site by sucking blood from bleeding site during surgery on body tissue of patient and monitoring dark and deep surgical site, which operator cannot see with his or her naked eye, with small camera. The surgical instrument has substantially the same shape as a pair of scissors and includes first body, second body having shape symmetrical to that of the first body, hinge to which the first and second bodies cross and are rotatably coupled, and photographing unit provided in the hinge to photograph a surgical site between front ends of the first and second bodies. The photographing unit may include camera mounted in the hinge such that lens of the camera can be exposed through the center of the front surface of the hinge and configured to transmit photographed image data to monitor. | 11-11-2010 |
20100274097 | Surgical instrument - Provided is a surgical instrument which can provide a field of view over a surgical site by sucking blood from a bleeding site during surgery such as tissue dissection and illuminating a dark and deep surgical site. The surgical instrument includes a first body including at least one suction port provided at a front end thereof, a second body configured to cross the first body and to be rotatably coupled to the first body, a suction unit provided in the first body to suck blood from a bleeding site of a patient through the suction port during surgery, and an illuminator provided in the second body to illuminate a space between front ends of the first and second bodies. | 10-28-2010 |
20100230259 | PEDAL INPUT DEVICE WITH THREE ROTATIONAL DEGREES OF FREEDOM - A pedal input device includes a base plate; a rotation center portion provided at the center of the base plate; a contacting plate having a yaw switch contacting portion protruding downwards from lower surface of the contacting plate; a pedal plate carried by the contacting plate and foot-operated so as to cause a drive member to make three-degree-of-freedom movement; a pair of pitch switches installed on the base plate in an opposing relationship with each other; a pair of roll switches installed on the base plate in an perpendicular relationship to the pitch switches so that the roll switches can be alternately contacted to the contacting plate of the pedal plate; and a pair of yaw switches installed on the base plate in an spaced-apart relationship with each other so that the yaw switches can be alternately contacted to the yaw switch contacting portion as the pedal plate rotates. | 09-16-2010 |
20100016249 | CANCER SENSITIZER COMPRISING GLUCOSAMINE, GLUCOSAMINE DERIVATIVES OR SALTS THEREOF - Disclosed herein is a cancer sensitizer comprising glucosamine, a glucosamine derivative, or a salt thereof. When administered to patients with cancer, the cancer sensitizer functions to sensitize cancer cells to anticancer agents without producing side effects, thereby increasing the therapeutic efficiency of chemotherapy. | 01-21-2010 |
20090318981 | PIN ASSEMBLY FOR OPERATION - A pin assembly for operation includes a hollow pin for operation having a plurality of side holes defined through a wall thereof and a root part which is closed or open due to the presence of a through-hole; and a hollow support member having a pin fastening part formed therein in the shape of a groove to fasten one end of the pin for operation, and being open at both ends thereof, wherein the pin for operation is fastened to the pin fastening part of the support member, and by applying external force to one end of the support member, the pin for operation is inserted into a bone. | 12-24-2009 |
20090257639 | METHOD OF TRACKING EYEBALL IN EYEBALL TUMOR TREATMENT - Disclosed herein is a method of tracking the movement of an eyeball in eyeball tumor treatment. The method includes a calibration step of storing an actual length for each pixel of an image in a storage unit, a template image generation step of storing a patient's eyeball image as a template image of the patient's eyeball in the storage unit, an eyeball location tracking step of, during the treatment of the patient's eyeball, determining whether movement of the treatment image has occurred by comparing treatment images of the patient's eyeball in real time with the template image, and a control step of stopping the operation of the proton beam output device if the movement of the treatment image deviates from a preset tolerance range, and keeping operation of the proton beam output device normal if the movement of the treatment image is within the tolerance range. | 10-15-2009 |
20090074727 | METHOD OF TREATING SOLID TUMOR - The present invention provides a method of immune/gene combination therapy that has an effect of suppressing growth of an intractable solid tumor and is useful for treatment of such a tumor, and a therapeutic composition used for said method. | 03-19-2009 |
20090023894 | Neutralizing Antibody Against HGF - The neutralizing antibody against HGF binding to the inventive neutralizable epitope of HGF is capable of neutralizing HGF as a single agent, and can be effectively used for preventing and treating intractable diseases and cancers that are caused by binding of HGF to its receptor Met. | 01-22-2009 |